Providers' utilization and perceptions of warfarin dosing algorithms

Warfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range international normalized ratios (INRs). Despite widespread availability, providers' utilization and perceptions of warfarin algorithms i...

Full description

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 183; pp. 4 - 12
Main Authors Gardner, Trevor, Vazquez, Sara R., Kim, Kibum, Jones, Aubrey E., Witt, Daniel M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.11.2019
Subjects
Online AccessGet full text
ISSN0049-3848
1879-2472
1879-2472
DOI10.1016/j.thromres.2019.09.002

Cover

Abstract Warfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range international normalized ratios (INRs). Despite widespread availability, providers' utilization and perceptions of warfarin algorithms in real-world practice are unclear. Identifying perceptions and barriers to algorithm use may help attempts to improve warfarin therapy management. Anticoagulation providers' utilization and perceptions of warfarin dosing algorithms were assessed via a nationwide electronic survey. Of the 246 providers who completed the survey, 82% were pharmacists, and 69% had over five years' experience dosing warfarin. Warfarin dosing algorithms were deemed beneficial by 84% of respondents and 72% currently use a warfarin dosing algorithm in their practice at least occasionally. Pharmacists were least likely of anticoagulation providers to use algorithms, although this was not statistically significant (p = 0.12). Algorithm utilization also decreased as years of warfarin dosing experience increased, with the highest rate of usage noted in the first year of dosing warfarin. The most common reason providers gave for discontinuing algorithm use was that they no longer felt it was needed. In this study, clinic patient volume did not appear to be associated with algorithm utilization. Warfarin dosing algorithms are frequently used among anticoagulation providers, especially those new to dosing warfarin, but use is frequently not sustained over the long-term. Education on the continued benefits of warfarin dosing algorithms could increase long-term utilization, potentially improving patient outcomes. •Most providers generally find warfarin dosing algorithms beneficial.•Three out of 4 providers use a warfarin dosing algorithm in their current practice.•Warfarin algorithm utilization declines as years of experience increases.•Warfarin dosing algorithms restricting clinical judgement is a barrier to use.
AbstractList Warfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range international normalized ratios (INRs). Despite widespread availability, providers' utilization and perceptions of warfarin algorithms in real-world practice are unclear. Identifying perceptions and barriers to algorithm use may help attempts to improve warfarin therapy management. Anticoagulation providers' utilization and perceptions of warfarin dosing algorithms were assessed via a nationwide electronic survey. Of the 246 providers who completed the survey, 82% were pharmacists, and 69% had over five years' experience dosing warfarin. Warfarin dosing algorithms were deemed beneficial by 84% of respondents and 72% currently use a warfarin dosing algorithm in their practice at least occasionally. Pharmacists were least likely of anticoagulation providers to use algorithms, although this was not statistically significant (p = 0.12). Algorithm utilization also decreased as years of warfarin dosing experience increased, with the highest rate of usage noted in the first year of dosing warfarin. The most common reason providers gave for discontinuing algorithm use was that they no longer felt it was needed. In this study, clinic patient volume did not appear to be associated with algorithm utilization. Warfarin dosing algorithms are frequently used among anticoagulation providers, especially those new to dosing warfarin, but use is frequently not sustained over the long-term. Education on the continued benefits of warfarin dosing algorithms could increase long-term utilization, potentially improving patient outcomes. •Most providers generally find warfarin dosing algorithms beneficial.•Three out of 4 providers use a warfarin dosing algorithm in their current practice.•Warfarin algorithm utilization declines as years of experience increases.•Warfarin dosing algorithms restricting clinical judgement is a barrier to use.
Warfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range international normalized ratios (INRs). Despite widespread availability, providers' utilization and perceptions of warfarin algorithms in real-world practice are unclear. Identifying perceptions and barriers to algorithm use may help attempts to improve warfarin therapy management. Anticoagulation providers' utilization and perceptions of warfarin dosing algorithms were assessed via a nationwide electronic survey. Of the 246 providers who completed the survey, 82% were pharmacists, and 69% had over five years' experience dosing warfarin. Warfarin dosing algorithms were deemed beneficial by 84% of respondents and 72% currently use a warfarin dosing algorithm in their practice at least occasionally. Pharmacists were least likely of anticoagulation providers to use algorithms, although this was not statistically significant (p = 0.12). Algorithm utilization also decreased as years of warfarin dosing experience increased, with the highest rate of usage noted in the first year of dosing warfarin. The most common reason providers gave for discontinuing algorithm use was that they no longer felt it was needed. In this study, clinic patient volume did not appear to be associated with algorithm utilization. Warfarin dosing algorithms are frequently used among anticoagulation providers, especially those new to dosing warfarin, but use is frequently not sustained over the long-term. Education on the continued benefits of warfarin dosing algorithms could increase long-term utilization, potentially improving patient outcomes.
Warfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range international normalized ratios (INRs). Despite widespread availability, providers' utilization and perceptions of warfarin algorithms in real-world practice are unclear. Identifying perceptions and barriers to algorithm use may help attempts to improve warfarin therapy management.INTRODUCTIONWarfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range international normalized ratios (INRs). Despite widespread availability, providers' utilization and perceptions of warfarin algorithms in real-world practice are unclear. Identifying perceptions and barriers to algorithm use may help attempts to improve warfarin therapy management.Anticoagulation providers' utilization and perceptions of warfarin dosing algorithms were assessed via a nationwide electronic survey.METHODSAnticoagulation providers' utilization and perceptions of warfarin dosing algorithms were assessed via a nationwide electronic survey.Of the 246 providers who completed the survey, 82% were pharmacists, and 69% had over five years' experience dosing warfarin. Warfarin dosing algorithms were deemed beneficial by 84% of respondents and 72% currently use a warfarin dosing algorithm in their practice at least occasionally. Pharmacists were least likely of anticoagulation providers to use algorithms, although this was not statistically significant (p = 0.12). Algorithm utilization also decreased as years of warfarin dosing experience increased, with the highest rate of usage noted in the first year of dosing warfarin. The most common reason providers gave for discontinuing algorithm use was that they no longer felt it was needed. In this study, clinic patient volume did not appear to be associated with algorithm utilization.RESULTSOf the 246 providers who completed the survey, 82% were pharmacists, and 69% had over five years' experience dosing warfarin. Warfarin dosing algorithms were deemed beneficial by 84% of respondents and 72% currently use a warfarin dosing algorithm in their practice at least occasionally. Pharmacists were least likely of anticoagulation providers to use algorithms, although this was not statistically significant (p = 0.12). Algorithm utilization also decreased as years of warfarin dosing experience increased, with the highest rate of usage noted in the first year of dosing warfarin. The most common reason providers gave for discontinuing algorithm use was that they no longer felt it was needed. In this study, clinic patient volume did not appear to be associated with algorithm utilization.Warfarin dosing algorithms are frequently used among anticoagulation providers, especially those new to dosing warfarin, but use is frequently not sustained over the long-term. Education on the continued benefits of warfarin dosing algorithms could increase long-term utilization, potentially improving patient outcomes.CONCLUSIONWarfarin dosing algorithms are frequently used among anticoagulation providers, especially those new to dosing warfarin, but use is frequently not sustained over the long-term. Education on the continued benefits of warfarin dosing algorithms could increase long-term utilization, potentially improving patient outcomes.
AbstractIntroductionWarfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range international normalized ratios (INRs). Despite widespread availability, providers' utilization and perceptions of warfarin algorithms in real-world practice are unclear. Identifying perceptions and barriers to algorithm use may help attempts to improve warfarin therapy management. MethodsAnticoagulation providers' utilization and perceptions of warfarin dosing algorithms were assessed via a nationwide electronic survey. ResultsOf the 246 providers who completed the survey, 82% were pharmacists, and 69% had over five years' experience dosing warfarin. Warfarin dosing algorithms were deemed beneficial by 84% of respondents and 72% currently use a warfarin dosing algorithm in their practice at least occasionally. Pharmacists were least likely of anticoagulation providers to use algorithms, although this was not statistically significant ( p = 0.12). Algorithm utilization also decreased as years of warfarin dosing experience increased, with the highest rate of usage noted in the first year of dosing warfarin. The most common reason providers gave for discontinuing algorithm use was that they no longer felt it was needed. In this study, clinic patient volume did not appear to be associated with algorithm utilization. ConclusionWarfarin dosing algorithms are frequently used among anticoagulation providers, especially those new to dosing warfarin, but use is frequently not sustained over the long-term. Education on the continued benefits of warfarin dosing algorithms could increase long-term utilization, potentially improving patient outcomes.
Author Witt, Daniel M.
Gardner, Trevor
Kim, Kibum
Vazquez, Sara R.
Jones, Aubrey E.
Author_xml – sequence: 1
  givenname: Trevor
  surname: Gardner
  fullname: Gardner, Trevor
  organization: University of Utah College of Pharmacy, Department of Pharmacotherapy, University of Utah, 30 South 2000 East Salt, Lake City, UT 84112, United States of America
– sequence: 2
  givenname: Sara R.
  orcidid: 0000-0002-9267-8980
  surname: Vazquez
  fullname: Vazquez, Sara R.
  email: sara.vazquez@hsc.utah.edu
  organization: University of Utah Health Thrombosis Center, 50 N Medical Drive Room 1R211, Salt Lake City, UT 84132, United States of America
– sequence: 3
  givenname: Kibum
  orcidid: 0000-0002-8676-7434
  surname: Kim
  fullname: Kim, Kibum
  organization: University of Utah College of Pharmacy, Department of Pharmacotherapy, University of Utah, 30 South 2000 East Salt, Lake City, UT 84112, United States of America
– sequence: 4
  givenname: Aubrey E.
  surname: Jones
  fullname: Jones, Aubrey E.
  organization: University of Utah College of Pharmacy, Department of Pharmacotherapy, University of Utah, 30 South 2000 East Salt, Lake City, UT 84112, United States of America
– sequence: 5
  givenname: Daniel M.
  surname: Witt
  fullname: Witt, Daniel M.
  organization: University of Utah College of Pharmacy, Department of Pharmacotherapy, University of Utah, 30 South 2000 East Salt, Lake City, UT 84112, United States of America
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31505378$$D View this record in MEDLINE/PubMed
BookMark eNqNUl1r3DAQFCWluaT9C8Fv7YuvK8m2bCilIf1IIdBC8y5kaZXoaktXyU5Jf33lXO4lD0lgQSzMzO6M9ogc-OCRkBMKawq0eb9ZT9cxjBHTmgHt1pAL2Auyoq3oSlYJdkBWAFVX8rZqD8lRShsAKmhXvyKHnNZQc9GuyOefMdw4gzG9LebJDe6fmlzwhfKm2GLUuF3aVARb_FXRquh8YUJy_qpQw1WIbroe02vy0qoh4Zv795hcfv1yeXZeXvz49v3s9KLUlWinkkMnRMe5YaJiFcsrWARad0wzhQwFKLC21xxMr3puG9pbzqCqG6yNpYYfk3c72W0Mf2ZMkxxd0jgMymOYk2SsbUWdvdcZenIPnfsRjdxGN6p4K_fGM-DDDqBjSCmildpNd9anqNwgKcglZ7mR-5zlkrOEXMAyvXlA3094kvhpR8Sc043DKJN26DUaF1FP0gT3tMTHBxJ6cN5pNfzGW0ybMEeff0FSmZgE-Wu5guUIaMeBd23zuMBzNvgPqprGkA
CitedBy_id crossref_primary_10_1016_j_tru_2021_100093
crossref_primary_10_1016_j_thromres_2021_10_003
Cites_doi 10.1007/s11239-015-1319-y
10.1002/phar.1991
10.1111/j.1538-7836.2009.03652.x
10.1016/j.thromres.2014.11.033
10.1001/jama.2017.11469
10.1038/clpt.2008.10
10.1111/j.1468-1331.2012.03772.x
10.1161/STR.0000000000000046
10.1161/CIRCULATIONAHA.112.101808
10.1160/TH11-05-0353
10.1161/STR.0000000000000024
10.1111/j.1538-7836.2008.02959.x
10.1016/j.arth.2009.07.021
10.1016/j.thromres.2012.11.016
ContentType Journal Article
Copyright 2019 Elsevier Ltd
Copyright © 2019 Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2019 Elsevier Ltd
– notice: Copyright © 2019 Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.thromres.2019.09.002
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-2472
EndPage 12
ExternalDocumentID 31505378
10_1016_j_thromres_2019_09_002
S0049384819303986
1_s2_0_S0049384819303986
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29Q
3O-
4.4
457
4CK
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEB
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OC~
OO-
OZT
P-8
P-9
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
WUQ
X7M
Z5R
ZGI
~G-
~HD
0SF
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
NCXOZ
RIG
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c478t-30977933d274242505fe01592c2ae2e70a0ffbc30dbab3f61bf320456e5df1d3
IEDL.DBID .~1
ISSN 0049-3848
1879-2472
IngestDate Thu Oct 02 11:28:14 EDT 2025
Thu Apr 03 07:01:38 EDT 2025
Thu Oct 02 04:26:46 EDT 2025
Thu Apr 24 23:03:50 EDT 2025
Sun Apr 06 06:53:57 EDT 2025
Tue Feb 25 19:58:29 EST 2025
Tue Oct 14 19:36:08 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Warfarin
TTR
MA
Nomogram
Perception
Barrier
LPN
INR
DOAC
Algorithm
Provider
time within therapeutic range
medical assistant
international normalized ratio
direct oral anticoagulant
licensed practical nurse
Language English
License Copyright © 2019 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c478t-30977933d274242505fe01592c2ae2e70a0ffbc30dbab3f61bf320456e5df1d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9267-8980
0000-0002-8676-7434
PMID 31505378
PQID 2288752475
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2288752475
pubmed_primary_31505378
crossref_citationtrail_10_1016_j_thromres_2019_09_002
crossref_primary_10_1016_j_thromres_2019_09_002
elsevier_sciencedirect_doi_10_1016_j_thromres_2019_09_002
elsevier_clinicalkeyesjournals_1_s2_0_S0049384819303986
elsevier_clinicalkey_doi_10_1016_j_thromres_2019_09_002
PublicationCentury 2000
PublicationDate 2019-11-01
PublicationDateYYYYMMDD 2019-11-01
PublicationDate_xml – month: 11
  year: 2019
  text: 2019-11-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Thrombosis research
PublicationTitleAlternate Thromb Res
PublicationYear 2019
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Markel, York, Liston, Flynn, Barnes, Davis, Committee (bb0045) 2010; 25
Van Spall, Wallentin, Yusuf, Eikelboom, Nieuwlaat, Yang, Kabali, Reilly, Ezekowitz, Connolly (bb0080) 2012; 126
Yoo, Kwon, Jo, Kang, Kim (bb0060) 2012; 19
Meschia, Bushnell, Boden-Albala, Braun, Bravata, Chaturvedi, Creager, Eckel, Elkind, Fornage, Goldstein, Greenberg, Horvath, Iadecola, Jauch, Moore, Wilson, American Heart Association Stroke C, Council on C, Stroke N, Council on Clinical C, Council on Functional G, Translational B, Council on H (bb0035) 2014; 45
Poller, Keown, Ibrahim, Lowe, Moia, Turpie, Roberts, van den Besselaar, van der Meer, Tripodi, Palareti, Shiach, Bryan, Samama, Burgess-Wilson, Heagerty, Maccallum, Wright, Jespersen (bb0065) 2008; 6
Rosenman, Liu, Phatak, Qi, Teal, Nisi, Liu, Parr (bb0050) 2016; 23
Jeffrey WI. Oral anticoagulants 2011. In: Goodman and Gilman's: The Pharmacological Basis of Therapeutics [Internet]. (12th. [17–25]. Available from)
Gage, Bass, Lin, Woller, Stevens, Al-Hammadi, Li, Rodriguez, Miller, GA, Pendleton, Jaffer, King, Whipple, Porche-Sorbet, Napoli, Merritt, Thompson, Hyun, Anderson, Hollomon, Barrack, Nunley, Moskowitz, Davila-Roman, Eby (bb0020) 2017; 318
Gallagher, Setakis, Plumb, Clemens, van Staa (bb0010) 2011; 106
Mohammad, Korkis, Garwood (bb0055) 2017; 37
bb0085
Kim, Nieuwlaat, Connolly, Schulman, Meijer, Raju, Kaatz, Eikelboom (bb0075) 2010; 8
.
Cho, Delate, Witt, Clark (bb0040) 2015; 135
Gage, Eby, Johnson, Deych, Rieder, Ridker, Milligan, Grice, Lenzini, Rettie, Aquilante, Grosso, Marsh, Langaee, Farnett, Voora, Veenstra, Glynn, Barrett, McLeod (bb0025) 2008; 84
Witt, Clark, Kaatz, Schnurr, Ansell (bb0015) 2016; 41
Kernan, Ovbiagele, Black, Bravata, Chimowitz, Ezekowitz, Fang, Fisher, Furie, Heck, Johnston, Kasner, Kittner, Mitchell, Rich, Richardson, Schwamm, Wilson, American Heart Association Stroke Council CoC, Stroke Nursing CoCC, Council on Peripheral Vascular D (bb0030) 2014; 45
Grzymala-Lubanski, Sjalander, Renlund, Svensson, Sjalander (bb0070) 2013; 131
Van Spall (10.1016/j.thromres.2019.09.002_bb0080) 2012; 126
Yoo (10.1016/j.thromres.2019.09.002_bb0060) 2012; 19
Witt (10.1016/j.thromres.2019.09.002_bb0015) 2016; 41
Grzymala-Lubanski (10.1016/j.thromres.2019.09.002_bb0070) 2013; 131
Kernan (10.1016/j.thromres.2019.09.002_bb0030) 2014; 45
10.1016/j.thromres.2019.09.002_bb0005
Gage (10.1016/j.thromres.2019.09.002_bb0025) 2008; 84
Meschia (10.1016/j.thromres.2019.09.002_bb0035) 2014; 45
Poller (10.1016/j.thromres.2019.09.002_bb0065) 2008; 6
Kim (10.1016/j.thromres.2019.09.002_bb0075) 2010; 8
Cho (10.1016/j.thromres.2019.09.002_bb0040) 2015; 135
Gage (10.1016/j.thromres.2019.09.002_bb0020) 2017; 318
Gallagher (10.1016/j.thromres.2019.09.002_bb0010) 2011; 106
Mohammad (10.1016/j.thromres.2019.09.002_bb0055) 2017; 37
Markel (10.1016/j.thromres.2019.09.002_bb0045) 2010; 25
Rosenman (10.1016/j.thromres.2019.09.002_bb0050) 2016; 23
References_xml – volume: 131
  start-page: 130
  year: 2013
  end-page: 134
  ident: bb0070
  article-title: Computer aided warfarin dosing in the Swedish national quality registry AuriculA - algorithmic suggestions are performing better than manually changed doses
  publication-title: Thromb. Res.
– volume: 318
  start-page: 1115
  year: 2017
  end-page: 1124
  ident: bb0020
  article-title: Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial
  publication-title: JAMA
– volume: 106
  start-page: 968
  year: 2011
  end-page: 977
  ident: bb0010
  article-title: Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
  publication-title: Thromb. Haemost.
– volume: 126
  start-page: 2309
  year: 2012
  end-page: 2316
  ident: bb0080
  article-title: Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial
  publication-title: Circulation.
– volume: 135
  start-page: 267
  year: 2015
  end-page: 271
  ident: bb0040
  article-title: Thromboembolic and bleeding outcomes of extended duration low-intensity warfarin following elective total knee arthroplasty
  publication-title: Thromb. Res.
– ident: bb0085
  article-title: REDCap [11/12/2018]
– reference: Jeffrey WI. Oral anticoagulants 2011. In: Goodman and Gilman's: The Pharmacological Basis of Therapeutics [Internet]. (12th. [17–25]. Available from)
– volume: 41
  start-page: 187
  year: 2016
  end-page: 205
  ident: bb0015
  article-title: Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
  publication-title: J. Thromb. Thrombolysis
– reference: .
– volume: 19
  start-page: 1547
  year: 2012
  end-page: 1553
  ident: bb0060
  article-title: Age- and weight-adjusted warfarin initiation nomogram for ischaemic stroke patients
  publication-title: Eur. J. Neurol.
– volume: 45
  start-page: 3754
  year: 2014
  end-page: 3832
  ident: bb0035
  article-title: Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association
  publication-title: Stroke.
– volume: 37
  start-page: 1284
  year: 2017
  end-page: 1297
  ident: bb0055
  article-title: Incorporating comprehensive management of direct oral anticoagulants into anticoagulation clinics
  publication-title: Pharmacotherapy.
– volume: 23
  year: 2016
  ident: bb0050
  article-title: Pharmacologic prophylaxis for venous thromboembolism among patients with total joint replacement: an electronic medical records study
  publication-title: Am. J. Ther.
– volume: 6
  start-page: 935
  year: 2008
  end-page: 943
  ident: bb0065
  article-title: An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage
  publication-title: J. Thromb. Haemost.
– volume: 8
  start-page: 101
  year: 2010
  end-page: 106
  ident: bb0075
  article-title: Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study
  publication-title: J. Thromb. Haemost.
– volume: 84
  start-page: 326
  year: 2008
  end-page: 331
  ident: bb0025
  article-title: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
  publication-title: Clin. Pharmacol. Ther.
– volume: 45
  start-page: 2160
  year: 2014
  end-page: 2236
  ident: bb0030
  article-title: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association
  publication-title: Stroke.
– volume: 25
  year: 2010
  ident: bb0045
  article-title: Venous thromboembolism: management by American Association of Hip and Knee Surgeons
  publication-title: J. Arthroplast.
– volume: 41
  start-page: 187
  issue: 1
  year: 2016
  ident: 10.1016/j.thromres.2019.09.002_bb0015
  article-title: Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
  publication-title: J. Thromb. Thrombolysis
  doi: 10.1007/s11239-015-1319-y
– volume: 37
  start-page: 1284
  issue: 10
  year: 2017
  ident: 10.1016/j.thromres.2019.09.002_bb0055
  article-title: Incorporating comprehensive management of direct oral anticoagulants into anticoagulation clinics
  publication-title: Pharmacotherapy.
  doi: 10.1002/phar.1991
– volume: 8
  start-page: 101
  issue: 1
  year: 2010
  ident: 10.1016/j.thromres.2019.09.002_bb0075
  article-title: Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study
  publication-title: J. Thromb. Haemost.
  doi: 10.1111/j.1538-7836.2009.03652.x
– volume: 135
  start-page: 267
  issue: 2
  year: 2015
  ident: 10.1016/j.thromres.2019.09.002_bb0040
  article-title: Thromboembolic and bleeding outcomes of extended duration low-intensity warfarin following elective total knee arthroplasty
  publication-title: Thromb. Res.
  doi: 10.1016/j.thromres.2014.11.033
– ident: 10.1016/j.thromres.2019.09.002_bb0005
– volume: 318
  start-page: 1115
  issue: 12
  year: 2017
  ident: 10.1016/j.thromres.2019.09.002_bb0020
  article-title: Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial
  publication-title: JAMA
  doi: 10.1001/jama.2017.11469
– volume: 84
  start-page: 326
  issue: 3
  year: 2008
  ident: 10.1016/j.thromres.2019.09.002_bb0025
  article-title: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2008.10
– volume: 23
  issue: 2
  year: 2016
  ident: 10.1016/j.thromres.2019.09.002_bb0050
  article-title: Pharmacologic prophylaxis for venous thromboembolism among patients with total joint replacement: an electronic medical records study
  publication-title: Am. J. Ther.
– volume: 19
  start-page: 1547
  issue: 12
  year: 2012
  ident: 10.1016/j.thromres.2019.09.002_bb0060
  article-title: Age- and weight-adjusted warfarin initiation nomogram for ischaemic stroke patients
  publication-title: Eur. J. Neurol.
  doi: 10.1111/j.1468-1331.2012.03772.x
– volume: 45
  start-page: 3754
  issue: 12
  year: 2014
  ident: 10.1016/j.thromres.2019.09.002_bb0035
  article-title: Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association
  publication-title: Stroke.
  doi: 10.1161/STR.0000000000000046
– volume: 126
  start-page: 2309
  issue: 19
  year: 2012
  ident: 10.1016/j.thromres.2019.09.002_bb0080
  publication-title: Circulation.
  doi: 10.1161/CIRCULATIONAHA.112.101808
– volume: 106
  start-page: 968
  issue: 5
  year: 2011
  ident: 10.1016/j.thromres.2019.09.002_bb0010
  article-title: Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
  publication-title: Thromb. Haemost.
  doi: 10.1160/TH11-05-0353
– volume: 45
  start-page: 2160
  issue: 7
  year: 2014
  ident: 10.1016/j.thromres.2019.09.002_bb0030
  article-title: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association
  publication-title: Stroke.
  doi: 10.1161/STR.0000000000000024
– volume: 6
  start-page: 935
  issue: 6
  year: 2008
  ident: 10.1016/j.thromres.2019.09.002_bb0065
  article-title: An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage
  publication-title: J. Thromb. Haemost.
  doi: 10.1111/j.1538-7836.2008.02959.x
– volume: 25
  issue: 1
  year: 2010
  ident: 10.1016/j.thromres.2019.09.002_bb0045
  article-title: Venous thromboembolism: management by American Association of Hip and Knee Surgeons
  publication-title: J. Arthroplast.
  doi: 10.1016/j.arth.2009.07.021
– volume: 131
  start-page: 130
  issue: 2
  year: 2013
  ident: 10.1016/j.thromres.2019.09.002_bb0070
  article-title: Computer aided warfarin dosing in the Swedish national quality registry AuriculA - algorithmic suggestions are performing better than manually changed doses
  publication-title: Thromb. Res.
  doi: 10.1016/j.thromres.2012.11.016
SSID ssj0017195
Score 2.2706852
Snippet Warfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events associated with out-of-range...
AbstractIntroductionWarfarin dosing algorithms have proven beneficial in increasing time within therapeutic range (TTR) and decreasing adverse events...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 4
SubjectTerms Adult
Algorithm
Algorithms
Barrier
Cross-Sectional Studies
Female
Health Personnel - standards
Hematology, Oncology, and Palliative Medicine
Humans
Male
Nomogram
Perception
Provider
Warfarin
Warfarin - pharmacology
Warfarin - therapeutic use
Title Providers' utilization and perceptions of warfarin dosing algorithms
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0049384819303986
https://www.clinicalkey.es/playcontent/1-s2.0-S0049384819303986
https://dx.doi.org/10.1016/j.thromres.2019.09.002
https://www.ncbi.nlm.nih.gov/pubmed/31505378
https://www.proquest.com/docview/2288752475
Volume 183
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: AIKHN
  dateStart: 20160601
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect (Elsevier)
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: ACRLP
  dateStart: 20160601
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect (Elsevier)
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: AKRWK
  dateStart: 19720201
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3daxQxEB9KBfFF_PZaLREEn7aXTbKby2OpllNp8aFC30I-9cp197i94lv_die72VNRURT2ZZcMWYbJfGTmNwPwUlaGo1XmhZOOF8JzVRghfIERM_U0Um_7DP7pWT3_KN5dVBc7cDxiYVJZZdb9g07vtXX-Ms3cnK4Wi4TxFYqnbvAK1bCapbbbQsg0xeDwZlvmUcpSDVMMhCrS6u9QwpeHaRTBFYa1qcRL9f1O8_XKLwzU7xzQ3hCd3IO72YMkR8NP3oed0DyA26c5R_4QXn_I4LruFUGpWmagJTGNJ6tvZSykjeSLWUeMlRvi23RlQMzyU7tebD5fdY_g_OTN-fG8yLMSCifkbFNwio6c4tyn1KtIfk0MaOkVc8wEFiQ1NEbrODLfWB7r0kaeOtHXofKx9Pwx7DZtE54CwQDN1nHGAmdcVCxa1UdhtbW1c1K6CVQjf7TLfcTTOIulHgvGLvXIV534qik-lE1guqVbDZ00_kghR_brESeKmk2jsv83ytDlA9rpUndMU_2TEE1AbSl_kMO_2vXFKCMaD2nKvJgmtNe4iKEur5iQ1QSeDMKz5QFHl7zicrb3Hzvvw530NmAkn8HuZn0dnqOztLEH_Wk4gFtHb9_Pz74C5NAT4w
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jj9MwFH4aBgm4INaZshoJiVOmie3E9RHNogLTEYcizc3yCh11kqrpiBu_nefEKSBAIJBySvzk6NPzW_w2gJei1Ay1MsussCzjjslMc-4y9Jhzl4fcmS6CPzurph_42_PyfAcOh1qYmFaZZH8v0ztpnd6ME5rj1WIRa3y5ZLEbvEQxLCfVNbjOSyqiB3bwZZvnUYhC9mMMuMzi8u_KhC8O4iyCS_RrY46X7BqepvuVX2io31mgnSY6uQO3kwlJXvd_eRd2fH0PbsxSkPw-HL1P1XXtK4JstUyVlkTXjqy-5bGQJpDPeh3QWa6Ja-KdAdHLj816sfl02T6A-cnx_HCapWEJmeVisslYjpacZMzF2CuPhk3wqOoltVR76kWu8xCMZYi-NixUhQkstqKvfOlC4dhD2K2b2u8DQQ_NVGFCPaMMAQ1Gdm5YZUxlrRB2BOWAj7KpkXicZ7FUQ8bYhRpwVRFXleOT0xGMt3SrvpXGHynEAL8aCkVRtCmU9v9G6dt0QltVqJaqXP3ERSOQW8ofGPGvdn0x8IjCUxpDL7r2zRUuoijMS8pFOYK9nnm2GDC0yUsmJo_-Y-fncHM6n52q0zdn7x7DrfilL5h8Arub9ZV_ipbTxjzrTsZXH9gVeA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Providers%27+utilization+and+perceptions+of+warfarin+dosing+algorithms&rft.jtitle=Thrombosis+research&rft.au=Gardner%2C+Trevor&rft.au=Vazquez%2C+Sara+R&rft.au=Kim%2C+Kibum&rft.au=Jones%2C+Aubrey+E&rft.date=2019-11-01&rft.eissn=1879-2472&rft.volume=183&rft.spage=4&rft_id=info:doi/10.1016%2Fj.thromres.2019.09.002&rft_id=info%3Apmid%2F31505378&rft.externalDocID=31505378
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0049-3848&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0049-3848&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0049-3848&client=summon